文献速递乳腺癌泌尿男性生殖肿瘤消化系统肿瘤

多基因风险评分在英国癌症筛查中的应用:一项建模分析

Utility of polygenic risk scores in UK cancer screening: a modelling analysis.
PubMed 文献 · Lancet Oncol · 2023-05-10

该建模分析基于英国国家癌症登记数据(2016-18)及已发表的多基因风险评分(PRS)性能估计,评估了八种癌症中PRS分层筛查的获益与危害。模型显示,PRS定义的高风险五分位(20%)人群可捕获37%的乳腺癌、46%的前列腺癌、34%的结直肠癌等病例;将英国筛查项目扩展至PRS高风险五分位(乳腺癌40-49岁、结直肠癌50-59岁、前列腺癌60-69岁)每年最多可分别避免102、188、158例死亡,而同等资源用于全人群非分层筛查(48-49岁、58-59岁、68-69岁)每年最多分别避免80、155、95例死亡。作者认为,在有利假设下PRS分层筛查可能带来适度的效率增益,但需英国特异性整群随机试验来量化真实临床影响、成本和危害。

要点

  • PRS定义的高风险五分位(20%)人群估计捕获37%乳腺癌、46%前列腺癌、34%结直肠癌病例。
  • 扩展至PRS高风险五分位(乳腺癌40-49岁、结直肠癌50-59岁、前列腺癌60-69岁)每年最多避免102、188、158例死亡。
  • 同等资源下全人群非分层筛查(48-49岁、58-59岁、68-69岁)每年最多避免80、155、95例死亡。

核心结论

  • 在有利假设下,模型提示PRS分层筛查对乳腺癌、前列腺癌和结直肠癌的癌症检出和避免死亡可能有适度的潜在效率增益。
  • 将筛查限制于高风险分位意味着许多或大多数 incident 癌症将发生在被归为低风险的人群中。
  • 需英国特异性整群随机试验来量化真实临床影响、成本和危害。

研究设计与样本

  • 建模分析,使用英国国家癌症登记数据集(2016-18)的年龄分层癌症发病率及已发表的八种癌症当前、未来和优化PRS的受试者工作特征曲线下面积估计。
  • 针对五种PRS定义的高风险分位(前50%、20%、10%、5%、1%)和三种PRS工具(当前、未来、优化),计算癌症发生的相对比例、与英国人口平均相比的癌症发生比值比及终生癌症风险。
  • 结合PRS分层与癌症筛查工具,检查按年龄分层的最大可达到癌症检出率,并建模假设性英国PRS分层筛查新项目对癌症特异性生存的最大影响。

主要发现

  • PRS定义的高风险五分位(20%)估计捕获37%乳腺癌、46%前列腺癌、34%结直肠癌、29%胰腺癌、26%卵巢癌、22%肾癌、26%肺癌和47%睾丸癌病例。
  • 将英国筛查项目扩展至PRS定义的高风险五分位(乳腺癌40-49岁、结直肠癌50-59岁、前列腺癌60-69岁)每年最多可分别避免102、188、158例死亡。
  • 对48-49岁乳腺癌、58-59岁结直肠癌、68-69岁前列腺癌进行全人群非分层筛查将使用同等资源,每年最多分别避免80、155、95例死亡。
  • 这些最大模型数字将被PRS分析和癌症筛查的人群不完全接受、间期癌症、非欧洲血统及其他因素大幅减弱。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些最大模型数字将被PRS分析和癌症筛查的人群不完全接受、间期癌症、非欧洲血统及其他因素大幅减弱。
  • 需英国特异性整群随机试验来量化真实临床影响、成本和危害。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast, prostate, colorectal, pancreas, ovary, kidney, lung, and testicular cancer). METHODS: For this modelling analysis, we used age-stratified cancer incidences for the UK population from the National Cancer Registration Dataset (2016-18) and published estimates of the area under the receiver operating characteristic curve for current, future, and optimised PRS for each of the eight cancer types. For each of five PRS-defined high-risk quantiles (ie, the top 50%, 20%, 10%, 5%, and 1%) and according to each of the three PRS tools (ie, current, future, and optimised) for the eight cancers, we calculated the relative proportion of cancers arising, the odds ratios of a cancer arising compared with the UK population average, and the lifetime cancer risk. We examined maximal attainable rates of cancer detection by age stratum from combining PRS-based stratification with cancer screening tools and modelled the maximal impact on cancer-specific survival of hypothetical new UK programmes of PRS-stratified screening. FINDINGS: The PRS-defined high-risk quintile (20%) of the population was estimated to capture 37% of breast cancer cases, 46% of prostate cancer cases, 34% of colorectal cancer cases, 29% of pancreatic cancer cases, 26% of ovarian cancer cases, 22% of renal cancer cases, 26% of lung cancer cases, and 47% of testicular cancer cases. Extending UK screening programmes to a PRS-defined high-risk quintile including people aged 40-49 years for breast cancer, 50-59 years for colorectal cancer, and 60-69 years for prostate cancer has the potential to avert, respectively, a maximum of 102, 188, and 158 deaths annually. Unstratified screening of the full population aged 48-49 years for breast cancer, 58-59 years for colorectal cancer, and 68-69 years for prostate cancer would use equivalent resources and avert, respectively, an estimated maximum of 80, 155, and 95 deaths annually. These maximal modelled numbers will be substantially attenuated by incomplete population uptake of PRS profiling and cancer screening, interval cancers, non-European ancestry, and other factors. INTERPRETATION: Under favourable assumptions, our modelling suggests modest potential efficiency gain in cancer case detection and deaths averted for hypothetical new PRS-stratified screening programmes for breast, prostate, and colorectal cancer. Restriction of screening to high-risk quantiles means many or most incident cancers will arise in those assigned as being low-risk. To quantify real-world clinical impact, costs, and harms, UK-specific cluster-randomised trials are required. FUNDING: The Wellcome Trust.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Huntley C, Torr B, Sud A, et al. Utility of polygenic risk scores in UK cancer screening: a modelling analysis. Lancet Oncol. 2023. PMID: 37178708. doi:10.1016/S1470-2045(23)00156-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。